JP4604161B2 - フェニルアラニン誘導体 - Google Patents

フェニルアラニン誘導体 Download PDF

Info

Publication number
JP4604161B2
JP4604161B2 JP2000606620A JP2000606620A JP4604161B2 JP 4604161 B2 JP4604161 B2 JP 4604161B2 JP 2000606620 A JP2000606620 A JP 2000606620A JP 2000606620 A JP2000606620 A JP 2000606620A JP 4604161 B2 JP4604161 B2 JP 4604161B2
Authority
JP
Japan
Prior art keywords
alkyl
group
compound
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000606620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002544119A5 (https=
JP2002544119A (ja
Inventor
アール．ジュニア バーク、テレンス
ガオ、ヤン
ヤン、ダジュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2002544119A publication Critical patent/JP2002544119A/ja
Publication of JP2002544119A5 publication Critical patent/JP2002544119A5/ja
Application granted granted Critical
Publication of JP4604161B2 publication Critical patent/JP4604161B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2000606620A 1999-03-23 2000-03-23 フェニルアラニン誘導体 Expired - Fee Related JP4604161B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12604799P 1999-03-23 1999-03-23
US60/126,047 1999-03-23
PCT/US2000/008231 WO2000056760A1 (en) 1999-03-23 2000-03-23 Phenylalanine derivatives

Publications (3)

Publication Number Publication Date
JP2002544119A JP2002544119A (ja) 2002-12-24
JP2002544119A5 JP2002544119A5 (https=) 2007-04-19
JP4604161B2 true JP4604161B2 (ja) 2010-12-22

Family

ID=22422719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000606620A Expired - Fee Related JP4604161B2 (ja) 1999-03-23 2000-03-23 フェニルアラニン誘導体

Country Status (7)

Country Link
US (1) US7825216B2 (https=)
EP (1) EP1163262B1 (https=)
JP (1) JP4604161B2 (https=)
AT (1) ATE509026T1 (https=)
AU (1) AU770920C (https=)
CA (2) CA2368733C (https=)
WO (1) WO2000056760A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028577A2 (en) * 1999-10-22 2001-04-26 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain
US7871981B2 (en) 1999-10-22 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility, angiogenesis, and metastasis
US7425537B2 (en) 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
US6977241B2 (en) 2000-08-22 2005-12-20 The United States Of America As Represented By The Department Of Health & Human Services SH2 domain binding inhibitors
US6821979B2 (en) 2002-03-07 2004-11-23 Blanchette Rockefeller Neurosciences Institute Synergistic enhancement of cognitive ability
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
CN115192564B (zh) * 2022-05-23 2023-11-17 四川大学华西医院 一种苯丙氨酸衍生物、药物组合物及其在肿瘤治疗中的应用
CN117603075B (zh) * 2024-01-18 2024-04-12 深圳创元生物医药科技有限公司 一种碳13标记的3-羧酸苯丙氨酸的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1883113A (en) * 1932-10-18 new yoek
US3906031A (en) 1971-03-15 1975-09-16 Research Corp Novel 9-fluorenylmethoxycarbonyl compounds
US4394519A (en) 1982-01-19 1983-07-19 Research Corporation Amino acid blocking agents
US4879398A (en) 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
US5296608A (en) 1988-04-25 1994-03-22 Hoffman-La Roche Inc. Intermediates for analogs of tyrosine sulfate or tyrosine phosphate containing peptides
US5182263A (en) 1988-04-25 1993-01-26 Hoffmann-La Roche Inc. Analogs of tyrosine sulfate or tyrosine phosphate containing peptides
US5272268A (en) 1990-06-28 1993-12-21 Shionogi & Co., Ltd. Dipeptide derivatives
US5679842A (en) 1990-08-17 1997-10-21 Hoechst Aktiengesellschaft Process for the preparation of aminomethanephosphonic acid and aminomethylphosphinic acids
AU687754B2 (en) 1990-08-31 1998-03-05 Warner-Lambert Company Tachykinin antagonists
AU657498B2 (en) 1990-12-14 1995-03-16 Novartis Ag Biphenylyl compounds
DE4115468A1 (de) 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
US5200546A (en) 1991-09-30 1993-04-06 The United States Of America As Represented By The Department Of Health And Human Services Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis
US5587372A (en) 1991-12-12 1996-12-24 Roussel Uclaf Cephalosporins
TW399041B (en) 1992-09-09 2000-07-21 Hoechst Ag Substituted cyclohexane derivatives, the preparation and the use for treating diseases
WO1994007913A1 (en) 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5712395A (en) 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
JPH08503217A (ja) 1992-11-18 1996-04-09 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー 血小板糖タンパク質▲ＩＩ▼ｂ／▲ＩＩＩ▼ａの阻害剤として有用な複素環式環により結合された環状化合物
GB9302331D0 (en) 1993-02-05 1993-03-24 Smithkline Beecham Plc Process
WO1995001376A1 (en) 1993-06-30 1995-01-12 Pharmacia S.P.A. Peptide inhibitors of mitogenesis and motogenesis
EP0677581A4 (en) 1993-08-19 1995-12-06 Japan Tobacco Inc DNA WHICH CODES THE PLANT-BASED ATP-DEPENDENT FRUCTOSE-6-PHOSPHATE-1-PHOSPHOTRANSFERASE, A RECOMBINANT VECTOR CONTAINING THE SAME, AND A METHOD FOR CHANGING THE SUGAR CONTENT OF A PLANT PLANT THROUGH PLANT.
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
KR100378615B1 (ko) 1993-10-25 2003-10-10 파크데이비스앤드캄파니 단백질:파르네실트랜스퍼라제의치환된테트라및펜타펩티드억제제
US5576323A (en) 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6037134A (en) 1994-03-07 2000-03-14 New York University Medical Center Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5849510A (en) 1994-04-26 1998-12-15 Selectide Corporation Factor Xa inhibitors
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5786454A (en) 1994-09-16 1998-07-28 Washington University School Of Medicine Modified SH2 domains
WO1996023813A1 (en) * 1995-02-01 1996-08-08 Affymax Technologies N.V. Peptides and compounds that bind to sh2 domains
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
US5710129A (en) 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes
US5688992A (en) 1995-03-31 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5612370A (en) 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phenylglycine and phenylalaninen amido benzopyran derivatives
US5798374A (en) 1995-06-07 1998-08-25 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith
WO1996040115A1 (en) 1995-06-07 1996-12-19 Sugen, Inc. Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
WO1996040629A1 (en) 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
US5965558A (en) 1995-06-19 1999-10-12 Ontogen Corporation Modulators of proteins with phosphotyrosine recognition units
US5753687A (en) 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
IT1282022B1 (it) 1995-07-06 1998-03-06 Mini Ricerca Scient Tecnolog Procedimento per la produzione di carbammati aromatici
GB9517060D0 (en) 1995-08-17 1995-10-25 Ciba Geigy Ag Acylated oligopeptide derivatives
WO1997012903A1 (en) * 1995-10-04 1997-04-10 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5948658A (en) 1996-06-25 1999-09-07 The Trustees Of Columbia University In The City Of New York Anti-cocaine catalytic antibody
US5922697A (en) 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
SE9701718D0 (sv) 1997-05-07 1997-05-07 Astra Ab Analgesic peptidomimetic compounds
EP1019364B1 (en) * 1997-08-28 2004-06-09 Biovitrum Ab Inhibitors of protein tyrosine phosphatase
US6410585B1 (en) 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
US6022696A (en) 1998-04-02 2000-02-08 Washington State University Research Foundation Methods of identifying agonists or antagonists of angiotensin IV
US6228986B1 (en) 1998-04-13 2001-05-08 Ortho-Mcneil Pharmaceutical, Inc. Solid-phase synthesis of novel 14-membered macroycles for high throughput screening
US6307090B1 (en) 1999-01-22 2001-10-23 The United States Of America As Represented By The Department Of Health And Human Services Acylated oligopeptide derivatives having cell signal inhibiting activity
WO2000073326A2 (en) 1999-06-02 2000-12-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Redox-stable, non-phosphorylated cyclic peptide inhibitors of sh2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use

Also Published As

Publication number Publication date
AU3927600A (en) 2000-10-09
CA2368733C (en) 2014-10-07
ATE509026T1 (de) 2011-05-15
AU770920B2 (en) 2004-03-11
EP1163262B1 (en) 2011-05-11
AU770920C (en) 2004-10-07
CA2368733A1 (en) 2000-09-28
EP1163262A1 (en) 2001-12-19
JP2002544119A (ja) 2002-12-24
US7825216B2 (en) 2010-11-02
US20070219194A1 (en) 2007-09-20
WO2000056760A1 (en) 2000-09-28
CA2855415A1 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
JP7823181B2 (ja) Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物
JP6871310B2 (ja) ジペプチド及びトリペプチドエポキシケトンプロテアーゼ阻害剤
AU772024B2 (en) Inhibitors of urokinase and blood vessel formation
US7825216B2 (en) Phenylanine derivatives
US6933290B2 (en) 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives
JPH05230095A (ja) 治療薬としての新規５−アミノ−４−ヒドロキシヘキサン酸誘導体
RO119413B1 (ro) Derivaţi izosteri ai substratului aspartat proteazei, sărurile lor, compoziţii farmaceutice şi utilizare
KR19980703151A (ko) 락탐-함유 히드록삼산 유도체, 그의 제조 그리고 매트릭스 메탈로프로테아제의 억제제로서의 그의 용도
JPH02212434A (ja) レトロウイルスプロテアーゼインヒビターとしてのペプチドアイソスターの使用
WO2023155808A1 (zh) 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
JP2024088768A (ja) カンナビノイドプロドラッグ化合物
JP2002503714A (ja) 抗腫瘍剤
JP2016501848A (ja) 大環状化合物及びその使用
KR102413079B1 (ko) 돌라프로인-돌라이소류인 펩타이드의 유도체
US6977241B2 (en) SH2 domain binding inhibitors
US7226991B1 (en) Phenylalanine derivatives
US20030166572A1 (en) 2-Amino-3-hydroxy-4-tert-leucyl-amino-5 phenyl-pentanoic acid amide derivatives
KR101264934B1 (ko) 아미도메틸-치환1-(카르복시알킬)-시클로펜틸카보닐아미노-벤자제핀-ｎ-아세트산 유도체, 그것의 제조를 위한 공정 및 중간체 생성물및 이들 화합물을 포함하는 의약품
CN109796519A (zh) 一类甾体化合物及其应用
US7425537B2 (en) SH2 domain binding inhibitors
WO2019061812A1 (zh) 氨基酸骨架类新型cxcr4拮抗剂及其制备与生物医学应用
WO2004003005A2 (en) Sh2 domain binding inhibitors
KR20250001962A (ko) 신규한 헤미아스텔린 유도체 및 이의 용도
HK1243085A1 (en) Derivatives of dolaproine-dolaisoleuine peptides
JPH093095A (ja) 新規なフエネチルアミド誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100520

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100615

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100713

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100812

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100817

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100901

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131015

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees